Products

  1. Home
  2. Products
  3. Bone & Mineral Metabolism
  4. IDKmonitor® Infliximab Total ADA ELISA K 9654

IDKmonitor® Infliximab Total ADA ELISA K 9654

$859.00

In Stock

Method: ELISA
Sample Type (Matrix): Serum, EDTA Plasma
Sample Volume: 25 µl
Species: Human
Incubation time: 3h
Size: 96 wells
Regulatory Status: Health Canada Licensed.
Kit Manual: Download

The IDKmonitor® Infliximab Total ADA ELISA is intended for the determination of human antibodies against TNFα blocker infliximab (e.g. REMICADE®) in the presence of infliximab in EDTA plasma and serum.

This assay allows a reliable determination of ADA even in the presence of infliximab; therefore it is ideal for therapy monitoring when a measurable infliximab concentration is expected, for example shortly after the last infusion.

In combination with the drug level determination, the IDKmonitor® Infliximab Total ADA ELISA can help physicians monitor and optimize therapy early on.

Chronic inflammatory diseases like Crohn’s disease, ulcerative colitis, or rheumatoid arthritis are often treated with anti-TNFα antibodies which target directly the underlying inflammatory processes.

The clinical efficacy of an anti-TNFα therapy correlates with the trough level of the therapeutic antibody, the drug level just before the next application of the anti-TNFα antibody. Several factors influence the trough level, among them dosage and frequency of anti-TNFα blocker infusion, disease activity, individual pharmacokinetics, and immune reaction (formation of anti-drug antibodies, ADA). It is thought that ADA functionally neutralizes the therapeutic antibodies or induces their rapid elimination. Consequences of ADA formation can be therapy failure and allergic reactions during anti-TNFα antibody application.

 

Additional information

Weight35.5 oz
Dimensions6.5 × 10 × 4.5 in
Social media & sharing icons powered by UltimatelySocial

Become an IDK Insider!

Join our mailing list to receive the latest news and updates from Immundiagnostik, Inc.

 
 
 
 

You have Successfully Subscribed!